Participated · Series A · Aug 2026

Kynexis is developing KYN-5356, a potential first-in-class oral small-molecule inhibitor of KAT-II intended to reduce brain kynurenic acid (KYNA) and restore signaling involved in cognition. The company’s initial clinical focus is cognitive impairment associated with schizophrenia (CIAS), with plans to expand into other cognitive disorders including Alzheimer’s disease. KYN-5356 is the company’s most advanced program and has demonstrated favorable safety, central nervous system penetration, and dose-dependent reductions in cerebrospinal fluid KYNA in Phase 1. Kynexis has completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 trial of ~150 adults across 13 U.S. sites evaluating a 28-day adjunctive treatment and expects topline results by the end of 2026. The company has a U.S. subsidiary based in Cambridge, Massachusetts, and recently added senior business development leadership to support its clinical and corporate strategy.

Participated · Equity · Aug 2026

Slate Medicines is advancing a pipeline of migraine antibody therapeutics designed to go beyond existing CGRP-targeted treatments. Its lead candidate, SLTE-1009 (licensed from DartsBio Pharmaceuticals), is a monoclonal antibody that targets both PACAP and VIP, and the company’s second program, SLTE-2100, is a bispecific antibody combining CGRP and PACAP/VIP blockade. Slate plans to report Phase I safety and PK data for SLTE-1009 in mid-2027 and to start a Phase II migraine study in the second half of 2027. The company positions its dual-targeting approach as potentially offering greater efficacy versus PACAP-only therapies in a market where CGRP-targeted products generated roughly $5 billion in 2025 sales. Slate recently secured a $245 million financing via a reverse merger and private placement and had raised $130 million in a Series A earlier the same year, giving it runway into 2029.

Participated · Series B · Aug 2026

Expedition Therapeutics is developing next-generation oral small molecule therapies targeting inflammatory and respiratory diseases, with its lead program EXPD-101, a once-daily DPP1 inhibitor, currently in a global Phase 2 trial for COPD. The company reported that EXPD-101 was well tolerated in Phase 1 with no dose-limiting toxicities and showed dose-proportional pharmacokinetics supporting once-daily dosing. The first patient has been dosed in the Phase 2 COPD study, marking the company’s transition into mid-stage clinical development. Expedition combines translational expertise and clinical development experience with a platform for in-licensing global innovation. The recent $115 million Series B financing led by General Atlantic is intended to fund EXPD-101 through Phase 2, expand the company’s pipeline of therapies for inflammatory diseases, and further its research discovery efforts. Expedition is based in San Francisco and has announced board expansion tied to the financing.

Participated · Series A · Jun 2026

Founded in 2021, RQ Bio is developing long-acting monoclonal antibody therapeutics aimed at providing immediate and durable protection against seasonal influenza. Its lead programme, RQB01, is in IND-enabling studies and is designed to deliver broad strain coverage and extended duration of action via a differentiated dual mechanism targeting conserved epitopes. The company aims to provide season-long protection with a single administration, particularly for immunocompromised and high-risk patients. RQ Bio has an experienced team with prior success in developing long-acting antiviral antibodies and is backed by a syndicate of life sciences investors. The recent $115 million Series A will fund clinical development of RQB01 and further advance the company's antibody discovery platform. Leadership was strengthened with the appointment of Christian S. Schade as Executive Chairman.

Participated · Series A · May 2026

cAMPfield Therapeutics is a newly formed biotechnology company backed by Mountainfield Venture Partners and other life-science investors to advance licensed development-stage therapeutic candidates. Its CEO, Bill Gerhart, has more than two decades of experience in pulmonary, fibrosis, and inflammatory diseases and a track record of leading biotech exits. Other senior leaders include CTO Patricia Turney and global head of regulatory affairs Rita Shah. Public filings and reporting link cAMPfield to vTv Therapeutics' HPP737, a PDE4 inhibitor that has been studied in China for psoriasis, COPD, atopic dermatitis, and idiopathic pulmonary fibrosis, including an ongoing Phase 3 psoriasis trial there. The company's explicit pipeline needs are not detailed in the coverage, nor are financial metrics beyond the $180 million Series A. cAMPfield appears positioned to progress licensed candidates through clinical development with capital from its recent financing.